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Abstract
Background: Different methods exist to estimate smoking attributable cancer mortality rates
(Peto and Ezzati methods, as examples). However, the smoking attributable estimates using these
methods cannot be generalized to all population sub-groups. A simpler method has recently been
developed that can be adapted and applied to different population sub-groups. This study assessed
cumulative tobacco smoke damage (smoke load)/non-lung cancer mortality associations across
time from 1979 to 2003 among all Massachusetts males and ages 30–74 years, using this novel
methodology.
Methods: Annual lung cancer death rates were used as smoke load bio-indices, and age-adjusted
lung/all other (non-lung) cancer death rates were analyzed with linear regression approach. Non-
lung cancer death rates include all cancer deaths excluding lung. Smoking-attributable-fractions
(SAFs) for the latest period (year 2003) were estimated as: 1-(estimated unexposed cancer death
rate/observed rate).
Results: Male lung and non-lung cancer death rates have declined steadily since 1992. Lung and
non-lung cancer death rates were tightly and steeply associated across years. The slopes of the
associations analyzed were 1.69 (95% confidence interval (CI) 1.35–2.04, r = 0.90), and 1.36 (CI
1.14–1.58, r = 0.94) without detected autocorrelation (Durbin-Watson statistic = 1.8). The lung/
non-lung cancer death rate associations suggest that all-sites cancer death rate SAFs in year 2003
were 73% (Sensitivity Range [SR] 61–82%) for all ages and 74% (SR 61–82%) for ages 30–74 years.
Conclusion: The strong lung/non-lung cancer death rate associations suggest that tobacco smoke
load may be responsible for most prematurely fatal cancers at both lung and non-lung sites. The
present method estimates are greater than the earlier estimates. Therefore, tobacco control may
reduce cancer death rates more than previously noted.
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Background
Estimation of mortality caused by tobacco use is an essen-
tial basis for state, national, and international tobacco
control efforts. Cancer mortality, which accounts for an
estimated annual 1.4 million or one third of, deaths glo-
bally, due to smoking [1], is of particular importance.
Recent estimates of smoking-attributable cancer mortality
utilize lung cancer mortality data as an indicator of the
accumulated hazards of tobacco smoking and tightly link
several temporal, ethnic, and geographic cancer mortality
disparities to smoking [1,2]. However, those indirect esti-
mates have at least two flaws. In the authors' words, the
Peto estimates are based on a "simple halving of the excess
risk [linked to smoke exposure which] is obviously not a
satisfactory procedure, for it is crude and arbitrary and
may seriously underestimate some of the true hazards of
tobacco" [3]. And both estimates are based in part on the
Cancer Prevention Study (CPS) – II, which has considera-
ble selection, exposure misclassification, and other biases
[3-5]; and they may seriously underestimate the actual
smoking attributable mortality. Further, the absolute
death rates among the non-smokers and the smokers (and
thus the smoker/nonsmoker death rate ratios) in the CPS-
II study cannot be generalized over the US population
[3,6].
A simpler method for computing cumulative tobacco
smoke damage has recently been introduced. This method
utilizes the associations between lung cancer ("smoke-
load") and non-lung cancer death rates across all cancer
sites. The smoke-load method may be more representa-
tive, less biased, and provide better population-specific
smoking attributable fractions (SAFs) than prior methods
[7-9].
Since Peto's method was introduced in the 1990s [3], sev-
eral cancers have been found to be tobacco-related. These
include some of the most common cancers around the
world such as cancers of the stomach, liver, uterine cervix,
kidney (renal cell carcinoma), and myeloid leukemia. In
addition, the cancer risks of tobacco smoking when com-
bined with exposure to other known carcinogens are
greatly enhanced for some cancer sites (http:www.iarc.fr/
en/Media-Centre/IARC-Press-ReleaseArchives-2003-
1998/2002/IARC-monographs-pro gramme-declares-sec-
ond-hand-smoke-carcinogenic-to-humans).
In summary, different methods exist to estimate smoking
attributable cancer mortality rates (Peto and Ezzati meth-
ods, as examples). However, the smoking attributable
estimates using these methods cannot be generalized to
all population sub-groups. A simpler method has recently
been developed that can be adapted and applied to differ-
ent population sub-groups. The smoke-load method has
been applied to different populations at other time peri-
ods [6-9]. In this study, we assessed cumulative tobacco
smoke damage (smoke load)/non-lung cancer mortality
associations across time from 1979 to 2003 among all
Massachusetts males and ages 30–74 years.
Methods
The present analysis excludes certain groups with varia-
tions in cancer death rates due to causes other than smok-
ing in order to increase the sensitivity to detect
associations between smoking rates and non-lung cancer
death rates. Non-lung cancer deaths refer to death rates
from cancers other than lung cancer. Factors other than
smoking that are known to cause variations in cancer mor-
tality rates are: a) changes in female pharmacological
estrogen and anti-estrogen treatments, mammography, or
hysterectomy; b) child cancer treatment changes; c) stom-
ach cancer mortality declines from 1930 to approximately
1979 associated with historical changes in environmental
factors such as Helicobacter Pylori infection; d) historical
changes in the classification of general causes of death
such as changes in the International Classification of Dis-
eases (ICD) and changes associated with improved cancer
biopsy rates and classification associated with the 1970s
Medicare and 1971 National Cancer Acts; and g) less diag-
nostic specificity at older ages.
Each of the above factors are less likely to substantially
affect more recent triennial cancer death rates among mid-
dle-aged males, a population with high smoking preva-
lence and low cause of death misclassification rates [10].
Therefore, annual and triennial time-series rates among
males aged 30–74 years during the calendar years since
initiation of ICD 9th revision use in 1979 are analyzed in
this study. Non-lung-cancer death rates were determined
by subtracting lung-cancer rates from all sites cancer rates.
Published mortality rates per 100,000 from the National
Center for Health Statistics [11,12] were used adjusted to
the 2000 US Standard Million population. Lung cancer
death rates were used as a smoke load bioindex [7]. Linear
regression analyses were performed with lung and non-
lung cancer rate as the independent and dependent varia-
ble, respectively.
Smoking attributable fractions (SAF) and their sensitivity
range (SR) were calculated using the formula SAF = 1 –
(estimated unexposed cancer death rate)/(observed rate)
based on the observed lung/non-lung cancer death rate
relationship and 95% confidence intervals (CI) and esti-
mated all sites cancer death rate among unexposed per-
sons of 63 (SR 43 to 93) per 100,000. The unexposed rates
used are, respectively, the recent cancer death rates
observed among male South Asian Californians [13],
female Asian Indian Americans excluding breast, cervix,
endometrial, and ovary (female-specific) cancers, [13].BMC Cancer 2008, 8:341 http://www.biomedcentral.com/1471-2407/8/341
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The estimates based on the linear association of Massa-
chusetts male lung/non-lung cancer death rates across the
years 1979–1988 and 1995–2001 (when prostate cancer
death misclassification was rare) and the lung cancer
death rate observed among United States White male
"never-smokers" (16.8 lung cancer deaths/100,000 refer-
enced in Cancer Prevention Study II [CPS]) were multi-
plied by 0.75, which is the minimum reduction required
to adjust the rate from the CPS II age standard to the 2000
US age standard population [14].
Cancer death rates in the unexposed male population,
aged 30–74 years, were estimated by multiplying the all-
age male cancer death rates by 0.95, which is equal to the
ratio of ages 30–74 years/all ages Massachusetts male all
sites cancer death rates averaged across 2002–2003 per the
US Centers for Disease Control, Wide-ranging OnLine
Data for Epidemiologic Research system (CDC WON-
DER) [15].
Results
Massachusetts male cancer death rates peaked in the early
1990s, including the rates for all sites, and non-lung can-
cer death rates for all age groups and for the 30–74 years
age group (Figure 1). A plot of the annual lung cancer
death rates against their corresponding non-lung cancer
death rate reveals a strong lung/non-lung cancer death
rate association among males of all ages and an even
stronger association among males aged 30–74 years (Fig-
ures 2 and 3). The slopes of these associations are 1.69
(95% CI 1.35–2.04, r = 0.90), or 1.36 (CI 1.02–1.96, r =
0.95) when adjusted for possible autocorrelation) and
1.36 (CI 1.14–1.58, r = 0.94) without detected autocorre-
lation (Durbin-Watson statistic = 1.8), respectively.
Figure 3 also shows a scatterplot of the triennial rates from
1980–2003, the slope of which is 1.44 (CI 1.10–1.78, r =
0.97) without detected autocorrelation (Durbin-Watson
statistic = 1.98). The lung/non-lung cancer death rate
associations suggest that year 2003 all-sites male cancer
death rate SAFs are 73% (SR 61–82%) across all ages and
74% (SR 61–82%) for males aged 30–74 years, or 196
deaths per 100,000.
Discussion
The strong lung/non-lung cancer death rate associations
observed among Massachusetts males suggest that
tobacco smoke load is a potential cause of most prema-
turely fatal cancers in this population. These associations
suggest that all-sites cancer death rate SAFs are 73% (SR
61–82%) for males over all ages and 74% (SR 61–82%)
for males aged 30–74 years.
SAFs of age-adjusted cancer death rates calculated by this
methodology are substantially higher than the cancer
death rate SAFs calculated based on the CPS II relative
Male lung and non-lung cancer death rates by year and years of age in Massachusetts Figure 1
Male lung and non-lung cancer death rates by year and years of age in Massachusetts.
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risks. The present method incorporates all non-lung can-
cers; sizeable, representative, recent male populations;
and age-adjusted death rates, which are the most reliable
measure of progress in global action against cancer [16].
In contrast, previous calculations of SAF were generally
based on sometimes outdated lists of smoking-related
cancer sites [1,17]; tobacco smoke exposure based on
smoking status, which extensively underestimates or mis-
classifies due to brief, unrecognized, disregarded, unre-
called or secondhand smoke exposure [4,18]; as well as
select smaller, racially homogeneous populations, that are
unrepresentative of the general population or even of
Whites only [5,6,19].
The limitations of this study are noted. Extrapolation
from population-level associations has previously
resulted in inaccurate estimates of individual relative risk
due to the ecologic fallacy [20]. The results of these analy-
ses may be unrepresentative of the association among
females, in other US states, or of longer-term trends prior
to ICD-9. The associations observed do not distinguish
between types of smoking exposure due to in-utero, other
secondhand smoke, sensitive stage (teenage) [21], or
active smoking since smoke load reflects cumulative life-
time damage [22].
The validity of the present findings is reinforced by the
strong and consistently positive smoke load/cancer death
associations seen over time among both males of all ages
and aged 30–74 years. In an earlier analysis among Black
US males, lung cancer death rates predicted approxi-
mately 98% and 97% of the variances in non-lung cancer
death rates throughout the 34% rise from 1969–1990 and
the subsequent decline of 11% from 1990–2000, respec-
tively [8]. The present analysis of more recent, and more
representative data, including comprehensive smoke load
estimation, concurrent with outcome assessments is in
contrast to the use of less recent and less-representative
data reported in most cohort studies to date [4,5,19] and
less reliable and comprehensive point exposure measures.
Those measures are often based on single smoking self-
Scatter plot of male lung versus non-lung cancer death rates (earliest points and latest points) in Massachusetts (line segments  connect consecutive years) Figure 2
Scatter plot of male lung versus non-lung cancer death rates (earliest points and latest points) in Massachu-
setts (line segments connect consecutive years).
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report observations that were assessed as long as decades
before the measured outcomes [22].
SAFs can be inaccurate and misleading under various cir-
cumstances such as omission of certain smoking-attribut-
able cancers, use of unrepresentative relative risks,
misclassified exposure status, and incomplete disclosure
of assumptions concerning sensitivity. SAFs that are based
on site-specific cancer death relative risks assume that
smoking causes no cancer deaths at other cancer sites. The
error in this assumption has been shown repeatedly in
subsequent studies linking smoking to additional cancer
sites [23]. Artificially low relative risk estimates might
result from high smoke exposures and death rates among
"never smokers" in the cohort or from unrepresentatively
low exposures and death rates among "smokers" due to
Scatter plot of male lung cancer death rates versus all other cancer death rates at ages 30–74 years (earliest and latest points)  and from 1980 to 2003 by triennium in Massachusetts (line segments connect consecutive years) Figure 3
Scatter plot of male lung cancer death rates versus all other cancer death rates at ages 30–74 years (earliest 
and latest points) and from 1980 to 2003 by triennium in Massachusetts (line segments connect consecutive 
years).
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low prior smoking or accelerated quitting among smokers
informed of the risk of premature death.
Each of the above issues appears to be present in the CPS
II cohort and the smoke effect estimates that are based on
it. The CPS II definition of "lifelong never smoker" likely
included many irregular, brief, or forgetful smokers and
only excluded persistent, regular smokers (persons had
who smoked at least one cigarette per day for one year)
[24]. Most CPS II "smokers" resurveyed at twelve years
denied current smoking [4]. This might help to explain
the reason that concurrent national average male death
rates greatly exceeded the average CPS II male death rates
for all causes [4] and exceeded even the CPS II "smoker"
lung cancer death rate at ages 35–49 years [7,15,24].
The smoke load/non-lung cancer death rate ratios
observed in this study are remarkably consistent across
time. Smoke load variation provides a likely and possibly
causal explanation for a large majority of the cancer death
rate disparities studied to date (see results) [7,9,13]. Lung
cancer death rates (smoke load) can explain 88% of the
variance in non-lung-stomach-uterine corpus rates from
1985 to 2004 among Korean females [9]. The estimated
Korea female all-sites cancer death rate SAF in 2004 was
43% (sensitivity range 29–56%) [9]. Residual confound-
ing from smoke load variations [22] may be an explana-
tion for associations found in prior studies between
cancer deaths and other epidemiological risk factors, such
as cooking or outdoor air pollution, diets, industrial expo-
sures, or medical treatments, made independently of
smoking status or other poor proxies for smoke load [25-
29]. Alternatively, those non-tobacco exposures may the-
oretically cause premature lung and non-lung cancer
deaths in the same ratio as does smoke exposure.
Nonetheless, the temporal trends of lung cancer epidem-
ics in most countries seem to be more compatible with
smoking patterns than with cooking, other air pollution,
oral tobacco, or nutrition-driven epidemics. Other than
declining death rates attributable to effective treatments
for uterine, breast and cervical cancer, most currently
available cancer treatments may have as little effect on
smoke loads and premature mortality as treatments for
premature mortality due to HIV, Kaposi's sarcoma, and
pneumocystosis had before anti retrovirals were found
that reduced HIV loads [30].
Conclusion
In conclusion, the finding of consistent, strong associa-
tions observed between smoke load and most cancer mor-
tality and the large SAFs [7] stresses the significance of
increasing support for tobacco control research, science,
and policy. Further research is needed to develop bio-
chemical measures of individual smoke load, study cancer
disparities among larger racially diverse populations, and
examine the reasons for the varying degrees of association
observed between lung cancer and other cancer death
rates among various populations [7,9,13]. Until such val-
idated robust biochemical measures for individual
tobacco load are developed or refined, simpler and less
biased methods such as the smoke load method can be
adapted and applied to different population sub-groups.
Nonetheless, the improved ability to assess the popula-
tion effect of tobacco smoke damage can be used to better
inform cancer control policy including the regulation of
tobacco products and smoking in public places.
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